89 related articles for article (PubMed ID: 35943414)
1. Factors associated with severe or fatal clinical manifestations of SARS-CoV-2 infection after receiving the third dose of vaccine.
Corrao G; Franchi M; Cereda D; Bortolan F; Leoni O; Jara J; Valenti G; Pavesi G
J Intern Med; 2022 Nov; 292(5):829-836. PubMed ID: 35943414
[TBL] [Abstract][Full Text] [Related]
2. Vulnerability Predictors of Post-Vaccine SARS-CoV-2 Infection and Disease-Empirical Evidence from a Large Population-Based Italian Platform.
Corrao G; Franchi M; Cereda D; Bortolan F; Leoni O; Borriello CR; Della Valle PG; Tirani M; Pavesi G; Barone A; Ercolanoni M; Jara J; Galli M; Bertolaso G
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746453
[TBL] [Abstract][Full Text] [Related]
3. Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.
Corrao G; Franchi M; Cereda D; Bortolan F; Zoli A; Leoni O; Borriello CR; Valle GPD; Tirani M; Pavesi G; Barone A; Ercolanoni M; Jara J; Galli M; Bertolaso G; Mancia G
Lancet Infect Dis; 2022 May; 22(5):649-656. PubMed ID: 35093194
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
[TBL] [Abstract][Full Text] [Related]
5. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
7. Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
Hitchings MDT; Ranzani OT; Lind ML; Dorion M; D'Agostini TL; de Paula RC; de Paula OFP; de Moura Villela EF; Scaramuzzini Torres MS; de Oliveira SB; Schulz W; Almiron M; Said R; de Oliveira RD; Vieira da Silva P; de Araújo WN; Gorinchteyn JC; Dean NE; Andrews JR; Cummings DAT; Ko AI; Croda J
BMJ; 2022 Jun; 377():e070102. PubMed ID: 35697361
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
[TBL] [Abstract][Full Text] [Related]
9. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
10. Trends in occurrence of takotsubo syndrome and association with SARS-CoV-2 infection and COVID-19 vaccination.
Rosh B; Naoum I; Stein N; Jaffe R; Saliba W
J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):815-821. PubMed ID: 37577873
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study.
Ioannou GN; Locke ER; O'Hare AM; Bohnert ASB; Boyko EJ; Hynes DM; Berry K
Ann Intern Med; 2022 Mar; 175(3):352-361. PubMed ID: 34928700
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy.
Corrao G; Franchi M; Cereda D; Bortolan F; Leoni O; Vignati E; Pavesi G; Gori A
BMC Infect Dis; 2022 Nov; 22(1):844. PubMed ID: 36371165
[TBL] [Abstract][Full Text] [Related]
13. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
[TBL] [Abstract][Full Text] [Related]
14. Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection.
Franchi M; Pellegrini G; Cereda D; Bortolan F; Leoni O; Pavesi G; Galli M; Valenti G; Corrao G
J Infect Public Health; 2023 Aug; 16(8):1137-1141. PubMed ID: 37267680
[TBL] [Abstract][Full Text] [Related]
15. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
[TBL] [Abstract][Full Text] [Related]
18. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.
Yousaf AR; Cortese MM; Taylor AW; Broder KR; Oster ME; Wong JM; Guh AY; McCormick DW; Kamidani S; Schlaudecker EP; Edwards KM; Creech CB; Staat MA; Belay ED; Marquez P; Su JR; Salzman MB; Thompson D; Campbell AP;
Lancet Child Adolesc Health; 2022 May; 6(5):303-312. PubMed ID: 35216660
[TBL] [Abstract][Full Text] [Related]
19. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
